



Christine Massey <cmssyc@gmail.com>

FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Christine Massey <cmssyc@gmail.com>

Fri, Jan 14, 2022 at 1:32 PM

To: rafael.eskenazi@utoronto.ca

January 14, 2024

To:
Rafael Eskenazi, FIPP Director
Freedom of Information and Protection of Privacy Office
University of Toronto
Room 104, McMurrich Building
12 Queen's Park Crescent W.
Toronto, ON M5S 1A8
416 946-5835
rafael.eskenazi@utoronto.ca

Dear Mr. Eskenazi,

I require some general Information, as per *the Freedom of Information and Protection of Privacy Act (FIPPA)*. I understand that the \$5.00 application fee is **deferred** until the University resumes normal operations.

Description of Requested Records:

All records in the possession, custody or control of the University of Toronto that contain **additional details** (listed below) of the so-called "virus isolation" and "genome sequencing" procedures/methodologies and results that were reported on in the publication by Banerjee et al. entitled "Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2" published by the CDC: https://wwwnc.cdc.gov/eid/article/26/9/20-1495_article ("Author affiliations: ... University of Toronto, Toronto, Ontario, Canada (P. Budyłowski, N. Christie, A. Ghalami, A.J. McGeer, M. Ostrowski, R.A. Kozak, S. Mubareka)...")

Vero Cell Culture - Experimental Group Details:

- Pre-Experimental Details: The Cell Nutrient Solution (storage medium) quantity and dilution that the cell lines were stored in, in preparation of the experiment
- The quantity of material from (allegedly infected) mid-turbinate swab samples that was added to the cell culture experimental group (per well)
- Antibiotics Quantities for the cell culture experimental group (per well)
- Antifungals Quantities for the cell culture experimental group (per well)
- Fetal Bovine Serum Quantities and dilution for the cell culture experimental group (per well)
- The quantity and dilution of the Cell Nutrient Solution (DMEM) used in the experimental group (per well)
- Quantities of all other additives for the cell culture experimental group (per well)
- The number of wells used in the experimental Group
- The number of wells in the experimental group that experienced CPE
- Type and quantity of UTM/VTM used in the experimental group (used in the storage of swab specimens from the patient diagnosed with "the virus" - per swab)
- Any additional chemicals or components added to the experimental group, with quantities (per well)

Vero Cell Culture - "Mock Infected" / Control Group Details:

- Pre-Experimental Details: The Cell Nutrient Solution (storage medium) quantity and dilution that the cell lines were stored in, in preparation of the experiment

- The quantity of material from uninfected mid-turbinate swab samples that was added to the cell culture control group (per well)
- Antibiotics Quantities for the cell culture control group (per well)
- Antifungals Quantities for the cell culture control group (per well)
- Fetal Bovine Serum Quantities and dilution for the cell culture control group (per well)
- The quantity and dilution of the Cell Nutrient Solution (DMEM) used in the control group (per well)
- Quantities of all other additives for the cell culture control group (per well)
- The number of wells used in the control Group
- The number of wells in the control group that experienced CPE
- Type and quantity of UTM/VTM used in the control group (used in the storage of control swab specimens from a patient considered free of "the virus" - per swab)
- Any additional chemicals or components added to the control group, with quantities (per well)

"Genome Sequencing" - Purity and Control Details:

- The degree of purity of the "virus" sample used in the sequencing experiment.
- All details of the control group that was used when comparing the results of sequencing:
 - the total nucleic acid extracted from the "viral lysate" (from the experimental group), versus
 - the total nucleic acid extracted from the non-viral lysate (from the control group).

In summary, please provide all records that include any additional details of the experimental and/or control groups that were used when "isolating and sequencing the virus".

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Format:

Pdf documents sent to me via email; I do not wish for anything to be shipped to me.

Contact Information:

Last name: Massey

First name: Christine

Address: [REDACTED] Peterborough, ON, Canada

Phone: [REDACTED]

Email: cmssyc@gmail.com

Thank you in advance and best wishes,
Christine Massey, M.Sc.



Christine Massey <cmssyc@gmail.com>

RE: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Kelly Carmichael <kelly.carmichael@utoronto.ca>
To: "cmssyc@gmail.com" <cmssyc@gmail.com>
Cc: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Tue, Feb 1, 2022 at 3:35 PM

Dear Christine Massey,

Please find attached the University's access decision for you request submitted below on January 14.

The attachment is encrypted with a password which I will provide to you by telephone.

If you have any questions regarding the decision or are not able to open the attachment, please let me know.

Sincerely,

Kelly Carmichael (she/her)

Coordinator

Freedom of Information and Protection of Privacy

University of Toronto

Room 104, McMurich Building

12 Queen's Park Crescent W.

Toronto, ON M5S 1A8

416-946-7303



From: Christine Massey <cmssyc@gmail.com>

Sent: January 14, 2022 1:32 PM

To: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Subject: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details



Christine Massey <cmssyc@gmail.com>

RE: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Kelly Carmichael <kelly.carmichael@utoronto.ca>
To: Christine Massey <cmssyc@gmail.com>
Cc: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Tue, Feb 1, 2022 at 4:58 PM

Hi Christine,

The password is: uOt220003CM

Best,

Kelly Carmichael (she/her)

Coordinator

Freedom of Information and Protection of Privacy

University of Toronto

Room 104, McMurich Building

12 Queen's Park Crescent W.

Toronto, ON M5S 1A8

416-946-7303



From: Christine Massey <cmssyc@gmail.com>

Sent: February 1, 2022 4:54 PM

To: Kelly Carmichael <kelly.carmichael@utoronto.ca>

Cc: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Subject: Re: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Hi Kelly,

I am not concerned about a security risk, so yes I consent to receiving the password via email.



FREEDOM OF INFORMATION & PROTECTION OF PRIVACY OFFICE

February 1, 2022

Christine Massey

Peterborough, ON, Canada

Delivered via E-Mail (cmssyc@gmail.com)

Dear Christine Massey,

Re: Request #22-0003 Access Decision

Thank you for your request under the *Freedom of Information and Protection of Privacy Act* (FIPPA) for:

All records in the possession, custody or control of the University of Toronto that contain additional details (listed below) of the so-called "virus isolation" and "genome sequencing" procedures/methodologies and results that were reported on in the publication by Banerjee et al. entitled "Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2" published by the CDC: https://wwwnc.cdc.gov/eid/article/26/9/20-1495_article ("Author affiliations: ... University of Toronto, Toronto, Ontario, Canada (P. Budylowski, N. Christie, A. Ghalami, A.J. McGeer, M. Ostrowski, R.A. Kozak, S. Mubareka)..."

Vero Cell Culture - Experimental Group Details:

- *Pre-Experimental Details: The Cell Nutrient Solution (storage medium) quantity and dilution that the cell lines were stored in, in preparation of the experiment*
- *The quantity of material from (allegedly infected) mid-turbinate swab samples that was added to the cell culture experimental group (per well)*
- *Antibiotics Quantities for the cell culture experimental group (per well)*
- *Antifungals Quantities for the cell culture experimental group (per well)*
- *Fetal Bovine Serum Quantities and dilution for the cell culture experimental group (per well)*
- *The quantity and dilution of the Cell Nutrient Solution (DMEM) used in the experimental group (per well)*
- *Quantities of all other additives for the cell culture experimental group (per well)*
- *The number of wells used in the experimental Group*

- *The number of wells in the experimental group that experienced CPE*
- *Type and quantity of UTM/VTM used in the experimental group (used in the storage of swab specimens from the patient diagnosed with "the virus" - per swab)*
- *Any additional chemicals or components added to the experimental group, with quantities (per well)*

Vero Cell Culture - "Mock Infected" / Control Group Details:

- *Pre-Experimental Details: The Cell Nutrient Solution (storage medium) quantity and dilution that the cell lines were stored in, in preparation of the experiment*
- *The quantity of material from uninfected mid-turbinate swab samples that was added to the cell culture control group (per well)*
- *Antibiotics Quantities for the cell culture control group (per well)*
- *Antifungals Quantities for the cell culture control group (per well)*
- *Fetal Bovine Serum Quantities and dilution for the cell culture control group (per well)*
- *The quantity and dilution of the Cell Nutrient Solution (DMEM) used in the control group (per well)*
- *Quantities of all other additives for the cell culture control group (per well)*
- *The number of wells used in the control Group*
- *The number of wells in the control group that experienced CPE*
- *Type and quantity of UTM/VTM used in the control group (used in the storage of control swab specimens from a patient considered free of "the virus" - per swab)*
- *Any additional chemicals or components added to the control group, with quantities (per well)*

"Genome Sequencing" - Purity and Control Details:

- *The degree of purity of the "virus" sample used in the sequencing experiment.*
- *All details of the control group that was used when comparing the results of sequencing:*
 - *the total nucleic acid extracted from the "viral lysate" (from the experimental group), versus*
 - *the total nucleic acid extracted from the non-viral lysate (from the control group).*

In summary, please provide all records that include any additional details of the experimental and/or control groups that were used when "isolating and sequencing the virus".

It is the decision of the University that FIPPA does not apply to the requested records, because you have requested records related to research conducted by employees or persons associated with an educational institution or hospital, which are excluded from FIPPA pursuant to section 65(8.1).

Consistent with FIPPA section 65(9), the subject-matter of the research is infectious diseases as more particularly described in the abstract of the subject paper, and the funding sources for the

research described in the subject paper are disclosed in the acknowledgements section of the paper as further reported in the publicly available websites of those funding sources.

FIPPA section 50(1) allows you to appeal any decision made by the University, within 30 days, by notifying the Information and Privacy Commissioner/Ontario (the IPC). Therefore, you may appeal this decision within thirty days of the date of this letter. The IPC's contact information is as follows:

2 Bloor Street East
Suite 1400
Toronto, Ontario M4W 1A8
Telephone: (416) 326-3333 (Toll Free: 1-800-387-0073)
Email: info@ipc.on.ca

If you choose to appeal this decision, you should quote the above file number to the IPC and provide a copy of your original request and this decision letter. You will also be required to provide the IPC with an appeal fee of \$25.00.

If you have any questions, please do not hesitate to contact me via email at kelly.carmichael@utoronto.ca or by telephone at 416-946-7303.

Sincerely,

K. Carmichael

Kelly Carmichael, Coordinator
Freedom of Information and Protection of Privacy Office



Christine Massey <cmssyc@gmail.com>

RE: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Christine Massey <cmssyc@gmail.com>

Tue, Feb 1, 2022 at 5:24 PM

To: Kelly Carmichael <kelly.carmichael@utoronto.ca>

Cc: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Thanks Kelly.

Did you take the following into consideration when making your decision?

Obligation to disclose

11 (1) Despite any other provision of this Act, a head shall, as soon as practicable, disclose any record to the public or persons affected if the head has reasonable and probable grounds to believe that it is in the public interest to do so and that the record reveals a grave environmental, health or safety hazard to the public. R.S.O. 1990, c. F.31, s. 11 (1).

You might not be aware, but the existence of the alleged "SARS-COV-2" is in question by many serious people around the world, because the methodologies used in virology are blatantly unscientific and illogical. Virologists literally fabricate in silico (computer) sequences that have never been shown to correspond to anything in the physical realm, and call them "viral genomes", and most "cases" have been diagnosed based on a 100% meaningless and fraudulent sequence-based test (PCR).

And no "covid" test has ever been validated, or could be validated, due to the complete and utter absence of any pure sample of the alleged virus, anywhere in the world.

Below is part of a communication that I sent to the Metropolitan Police in London, England (re crime reference number 6029679/21; the entire email communication is attached).

1. An alleged "virus" must be purified (aka "isolated") before it can be sequenced, characterized, and investigated via controlled experiments.
2. Sequencing and characterization are necessary for identification of a specific alleged "virus".
3. Repeated controlled experiments are necessary for determination of disease causation by an alleged "virus".
4. Purification of an alleged "virus" from many patient samples, and then characterization, sequencing and repeated controlled experiments are necessary before one can logically and scientifically conclude that "it" is circulating in humans and is the cause of an allegedly new disease.
5. It is impossible to validate any "test" without a gold standard.
6. It is impossible to validate any "test" claimed to "confirm" the presence of a "virus" (or a "viral infection") before the alleged "virus" has been proven to exist.

7. It is impossible to validate any “test” claimed to “confirm” a “viral disease” before the alleged “virus” has been a) proven to exist and b) proven to cause the disease.

8. Published studies wherein authors claimed to have “isolated” the alleged “COVID-19 virus” (aka “SARS-COV-2”) (or any other alleged virus, including “SARS-COV-1”) do not describe isolation/purification of an alleged virus from patient samples (or from anything else).

9. Published studies wherein authors claimed to have “sequenced” the alleged “SARS-COV-2” (or any other alleged virus, including “SARS-COV-1”) do not describe extraction of genetic material from a purified sample of “virus” or discovery/determination of a “viral genome”. Rather, they describe the fabrication of an in silico (computer) sequence that they call a “viral genome” but has never been shown to correspond to anything in the physical realm.

10. Freedom of Information (FOI) responses from 47 Canadian institutions (including the Public Health Agency of Canada, Health Canada and all 5 Canadian institutions that claimed to have “isolated the virus”) and Freedom of Information responses and court documents from 118 additional institutions in roughly 30 additional countries show that governments and health/science institutions worldwide have uniformly failed to provide or cite even 1 record describing purification of the alleged “SARS-COV-2” (or any alleged “variant”) from a sample taken from a sick patient, by anyone, anywhere on Earth.

11. FOI responses from the U.S. Centers for Disease Control and Prevention and elsewhere yielded no record describing purification of the alleged 2003 “SARS virus” (or any “common cold coronavirus”) from a sample taken from a sick patient, by anyone, anywhere on Earth.

12. Governments and health/science institutions worldwide have demonstrated that they are unable to provide or cite any study or report, published by anyone, anywhere on Earth, describing the alleged “SARS-COV-2” isolated/purified directly from the fluids of a sick patient and then characterized and sequenced and proven to cause disease in humans or animals.

13. Governments and health/science institutions worldwide have demonstrated that they are unable to prove the existence of the alleged “SARS-COV-2” (or any alleged “variant”).

14. Governments and health/science institutions worldwide have demonstrated that they are unable to prove that the alleged “SARS-COV-2” (or any alleged “variant”) is the cause of any disease, new or old.

15. All of the above-mentioned FOI responses and court documents are publicly available at the following URL:

<https://www.fluoridefreepeel.ca/fois-reveal-that-health-science-institutions-aroundthe-world-have-no-record-of-sars-cov-2-isolation-purification/>

and in compilation pdfs in storage drives at the following URLs:

<https://tinyurl.com/IsolationFOIs>;

<http://bit.ly/awcevidence>.

16. All "COVID-19" tests, diagnoses, statistics, projections, models, injections, restrictions, requirements, and interferences of every kind are invalid and ultimately based on delusion, misconception, misinterpretation, ignorance, incompetence, incomplete information and/or intentional fraud.

Best wishes,
Christine

[Quoted text hidden]

4 attachments





Christine Massey <cmssyc@gmail.com>

RE: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Kelly Carmichael <kelly.carmichael@utoronto.ca>
To: Christine Massey <cmssyc@gmail.com>
Cc: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Wed, Feb 2, 2022 at 4:26 PM

Hi Christine,

Thank you for your email.

I can confirm that the University considered the Freedom of Information and Protection of Privacy Act in its entirety when making the decision set out in the Feb 1, 2022 decision letter

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

RE: FIPPA request to U of Toronto: Banerjee et al. "SARS-COV2 isolation" paper - unpublished details

Christine Massey <cmssyc@gmail.com>

Wed, Feb 2, 2022 at 8:47 PM

To: Kelly Carmichael <kelly.carmichael@utoronto.ca>

Cc: Rafael Eskenazi <rafael.eskenazi@utoronto.ca>

Thank you Kelly.

Did you also take into account the fact that releasing the required records would help expose the anti-science nature of virology and thus save many millions, even billions, of lives in the coming years? And that failing to release the records would potentially make you complicit in a coverup of scientific fraud and crimes against humanity?

Best wishes,
Christine

[Quoted text hidden]